CNDO News Alert Coronado Biosciences (CNDO) 2.13 12/25/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Coronado Biosciences (CNDO) 2.13 $CNDO

Autism - Pipeline Review, H2 2014
M2 - Fri Dec 19, 5:21AM CST
Research and Markets (http://www.researchandmarkets.com/research/rt9w3w/autism_pipeline) has announced the addition of the "Autism - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Autism, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Autism and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Autism - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Autism pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - F. Hoffmann-La Roche - Sumitomo Dainippon Pharma - Egenix - Novartis - Merz Pharma GmbH & Co - Mitsubishi Tanabe Pharma Corporation - Teva Pharmaceutical Industries - BrainStorm Cell Therapeutics - Avanir Pharmaceuticals - Curemark - Coronado Biosciences - Omeros Corporation - Intra-Cellular Therapies - Cellceutix Corporation - Heptares Therapeutics - Edison Pharmaceuticals - Otsuka Holdings - Reviva Pharmaceuticals - Naurex - Mnemosyne Pharmaceuticals - BioCrea - Saniona - Confluence Pharmaceuticals - MedDay For more information visit http://www.researchandmarkets.com/research/rt...m_pipeline
CNDO: 2.13 (+0.05), TEVA: 57.09 (+0.33), ITCI: 17.99 (+0.16), BCLI: 3.85 (+0.22), OMER: 22.09 (+0.48), NVS: 93.91 (+0.66)

Coronado Biosciences Announces Closing of Initial Public Offering of CB Pharma Acquisition Corp.
GlobeNewswire - Thu Dec 18, 7:15AM CST
Coronado Biosciences, Inc. (Nasdaq:CNDO) ("Coronado" or the "Company" reports the closing on December 17, 2014 of the initial public offering of CB Pharma Acquisition Corp. (Nasdaq:CNLMU) ("CB Pharma" . CB Pharma is a Cayman Islands exempted company formed as a blank check company for the purpose of entering into a business combination with one or more businesses or entities, with a current focus in the specialty pharma and generic drug industries, among others.
CNDO: 2.13 (+0.05), CNLMU: 10.02 (-0.01)

Coronado prices CB Pharma IPO
Seeking Alpha - at Seeking Alpha - Mon Dec 15, 9:58AM CST

CNDO: 2.13 (+0.05)

Coronado Biosciences Announces Pricing of Initial Public Offering of CB Pharma Acquisition Corp.
GlobeNewswire - Mon Dec 15, 7:15AM CST
Coronado Biosciences, Inc. (Nasdaq:CNDO) ("Coronado" or the "Company" reports the pricing on December 12, 2014 of the initial public offering of CB Pharma Acquisition Corp. (Nasdaq:CNLMU) ("CB Pharma" , a company which Coronado founded. CB Pharma is a Cayman Islands exempted company formed as a blank check company for the purpose of entering into a business combination with one or more businesses or entities, with a current focus in the specialty pharma and generic drug industries, among others.
CNDO: 2.13 (+0.05), CNLMU: 10.02 (-0.01)

Coronado Biosciences, Inc. (CNDO) in Focus: Stock Soars 17.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Nov 28, 8:18AM CST
Coronado Biosciences, Inc. (CNDO) was a big mover last session, as the company saw its shares rise by nearly 18% on the day.
ANIP: 55.24 (+1.79), CNDO: 2.13 (+0.05), AMAG: 43.02 (+0.90), AFFX: 9.80 (+0.05)

Coronado Bio powers up in late trading
Seeking Alpha - at Seeking Alpha - Wed Nov 26, 3:07PM CST

CNDO: 2.13 (+0.05)

Coronado Biosciences (CNDO) Jumps: Stock Rises 8.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Nov 25, 7:51AM CST
Coronado Biosciences, Inc. (CNDO) was a big mover last session, as its shares rose nearly 9% on the day.
BIIB: 340.89 (+5.13), CNDO: 2.13 (+0.05), ANIP: 55.24 (+1.79), AMAG: 43.02 (+0.90)

Warren Buffett Pick CBI Tumbles On Rating Downgrade
at The Street - Mon Nov 24, 12:00PM CST
Amicus Therapeutics, Inc. (NASDAQ:FOLD), Coronado Biosciences Inc (NASDAQ:CNDO) and Receptos Inc (NASDAQ:RCPT) hit midday posting major gains this Monday. Getting a sluggish start to the week are Fa...
CBI: 41.94 (-0.17), FATE: 4.90 (+0.23), CNDO: 2.13 (+0.05), RCPT: 122.05 (+4.05), FOLD: 7.94 (+0.06)

CB Pharma on deck for IPO
Seeking Alpha - at Seeking Alpha - Fri Nov 21, 10:46AM CST

IPO: 23.22 (+0.11), BIS: 47.26 (-1.74), BIB: 122.51 (+3.83), CNDO: 2.13 (+0.05), IBB: 299.80 (+5.12), DRGS: 53.60 (unch), IXJ: 100.54 (+0.55), IRY: 47.28 (-0.01)

Rackspace Bounces, Making Dan Loeb $34 Million In The Process
at The Street - Tue Nov 11, 1:06PM CST
Coronado Biosciences Inc (NASDAQ:CNDO), Rackspace Hosting, Inc. (NYSE:RAX) and AuRico Gold Inc (NYSE:AUQ) are making notable climbs on the stock market this Tuesday. Town Sports International Holding...
RDUS: 37.17 (+0.11), CLUB: 5.90 (-0.07), RAX: 48.24 (+0.45), CNDO: 2.13 (+0.05), AUQ: 3.08 (+0.10)

InsiderInsights.com Daily Round Up 11/10/14: CHK, TWX, SGEN, PBFX
InsiderInsights - at Seeking Alpha - Tue Nov 11, 2:29AM CST

HAS: 55.25 (+0.03), VR: 41.51 (+0.19), SEIC: 40.58 (+0.06), DRNA: 16.23 (-0.23), HA: 24.44 (+0.51), SAM: 292.15 (+1.62), PBFX: 18.81 (-0.14), AMRI: 15.19 (+0.05), GSAT: 2.97 (+0.03), TNET: 31.61 (+0.15), TWX: 85.58 (-0.20), HLT: 26.21 (+0.11), Q: 59.48 (+0.01), SGEN: 31.10 (-0.14), CF: 275.49 (-3.16), OPK: 9.63 (+0.21), CHK: 19.84 (-0.45), CNDO: 2.13 (+0.05), CO: 4.40 (+0.05), CPLA: 74.60 (-0.38)

Coronado Biosciences Raises $3,500,000 Through the Private Placement of Restricted Common Stock
GlobeNewswire - Fri Nov 07, 7:38AM CST
Shares were sold at the closing price on November 6, 2014
CNDO: 2.13 (+0.05)

Coronado Biosciences Reports Financial Results
GlobeNewswire - Thu Nov 06, 6:08AM CST
Coronado Biosciences, Inc. (Nasdaq:CNDO) announced its financial results for the third quarter ended September 30, 2014. Coronado's net cash and restricted cash totaled $71.6 million and $15.4 million respectively at September 30, 2014. The Company posted a quarterly net loss of $4.6 million and $16.7 million, or $0.13 and $0.46 per share for the three and nine months ended September 30, 2014 respectively. These results compare to a net loss of $7.8 million and $27.4 million, or $0.24 and $0.95 per share for the three and nine months ended September 30, 2013 respectively.
CNDO: 2.13 (+0.05)

EC approves ulcerative colitis med
Seeking Alpha - at Seeking Alpha - Wed Oct 22, 10:31AM CDT

SGYP: 3.08 (+0.12), JNJ: 104.59 (+0.31), ABT: 45.70 (-0.02), CNDO: 2.13 (+0.05), PFE: 31.42 (-0.03), SHPG: 209.29 (+0.07), VBLX: 11.15 (+0.15), SLXP: 114.92 (-1.18), RCPT: 122.05 (+4.05), ABBV: 66.21 (+1.86), ATHX: 1.30 (-0.03)

Coronado Biosciences Forms Subsidiary to Acquire and License Dermatology Products for Commercialization
GlobeNewswire - Wed Oct 08, 7:35AM CDT
Coronado Biosciences, Inc. (Nasdaq:CNDO) has formed a wholly owned subsidiary, Journey Medical Corporation (JMC), to acquire and license dermatology products. Under the leadership of Claude Maraoui, CEO, JMC will begin building a portfolio of dermatological assets focused on acne, steroid responsive dermatoses, pigmentation and antifungals for promotion to dermatologists and pediatricians.
CNDO: 2.13 (+0.05)

Kamada Plunges Following Missed Marks In Trial
at The Street - Thu Sep 04, 11:52AM CDT
UTi Worldwide Inc. (NASDAQ:UTIW), Flexion Therapeutics Inc (NASDAQ:FLXN) and PVH Corp (NYSE VH) are today's top-gaining billionaire stock picks midday. On the losing end are Kamada Ltd (NASDAQ:KM...
UTIW: 11.84 (+0.02), FLXN: 20.56 (+0.02), CNDO: 2.13 (+0.05), KMDA: 3.57 (-0.03), CIEN: 19.86 (+0.03), PVH: 125.44 (-0.94)

Coronado Falls on TSO Study Results - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jun 27, 10:20AM CDT
Coronado (CNDO) announced disappointing top-line results from a pilot study on TSO.
BIIB: 340.89 (+5.13), MDCO: 27.06 (+0.21), CNDO: 2.13 (+0.05), REGN: 400.12 (+6.07)

Coronado Biosciences Reports Topline Results From Investigator Initiated Pilot Study of TSO in Adults With Autism Spectrum Disorder
GlobeNewswire - Thu Jun 26, 7:50AM CDT
Coronado Biosciences, Inc. (Nasdaq:CNDO) today announced that Dr. Eric Hollander, Clinical Professor Psychiatry and Behavioral Sciences at Albert Einstein College of Medicine of Yeshiva University and Director of the Autism and Obsessive Compulsive Spectrum Program at Montefiore Medical Center and Einstein has completed his pilot study of oral TSO (Trichuris suis ova or CNDO-201) for adults with Autism Spectrum Disorder (ASD).
CNDO: 2.13 (+0.05)

Autism - Pipeline Review, H1 2014 - 20 Companies & 42 Drug Profiles
M2 - Fri Jun 20, 2:32AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ltzhjv/autism_pipeline) has announced the addition of the "Autism - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Autism, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Autism and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - F. Hoffmann-La Roche Ltd. - Dainippon Sumitomo Pharma Co., Ltd. - Novartis AG - Merz Pharma GmbH & Co. KgaA - Teva Pharmaceutical Industries Limited - Avanir Pharmaceuticals, Inc. - Snowdon Inc. - Curemark, LLC - Coronado Biosciences, Inc. - Omeros Corporation - Intra-Cellular Therapies, Inc. - Cellceutix Corporation - Heptares Therapeutics Ltd. - Otsuka Holdings Co., Ltd. - Reviva Pharmaceuticals Inc. - Naurex, Inc. - Nectid, Inc. - Mnemosyne Pharmaceuticals, Inc. - BioCrea GmbH - Saniona AB Drug Profiles - CM-AT - lurasidone hydrochloride - aripiprazole - cycloserine - fluoxetine - oxytocin - oxytocin - memantine hydrochloride - TSO - pioglitazone hydrochloride - oxytocin - oxytocin - (dextromethorphan hydrobromide quinidine sulfate) - oxytocin - oxytocin - RG-7314 - fluoxetine - fluoxetine - argipressin tannate - NU-211-01 NC-215-01 - Autologous Hematopoietic Stem Cells - glatiramer acetate - ITI-007 - Stem Cell Therapy for Central Nervous System Disorders - KM-391 - Program For Neurological Disorders - STX-110 - CN-2097 - acamprosate calcium - Small Molecules to Inhibit PI3K for Autism and Fragile X Syndrome For more information visit http://www.researchandmarkets.com/research/lt...m_pipeline
CNDO: 2.13 (+0.05), TEVA: 57.09 (+0.33), ITCI: 17.99 (+0.16), OMER: 22.09 (+0.48), NVS: 93.91 (+0.66)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Pinnacol’s Community Work Earns Denver Chamber Recognition

Updated Category News Views 67

A workers’ comp insurer usually becomes visible on somebody’s worst day; Pinnacol Assurance is being recognized for the work it keeps doing around those days. The Denver Metro Chamber of Commerce has given the Colorado-based, member-owned carrier its 2026 Business Impact Award for Corporate Social Responsibility. Awards can be cheap applause, frankly. This one...

Continue Reading
CVRx Lawsuit Puts a Hard Date on Investor Decisions

Updated Category News Views 65

One ugly filing after the bell can vaporize years of shareholder confidence, and CVRx just supplied the painful exhibit. On August 7, 2026, shares of CVRx fell $3.55, or 59.76%, to close at $2.39 after the company disclosed a U.S. Department of Justice civil investigative demand in its August 6 Form 10-Q. That is not a routine bad quarter. It is the sort of disclosure...

Continue Reading
Lymphatic Research Gains Attention Beyond Wellness Claims

Updated Category News Views 23

Ankles leave little clues after a long day: sock grooves, puffiness, that dull heaviness nobody bothers to name. PureHealth Research wants people to look past the usual salt-and-water explanation and consider the lymphatic system, the body’s comparatively unsung network for gathering fluid from tissues and returning it to the bloodstream. Fair enough. This system does...

Continue Reading
Tigerlily Brings HIV Information to Women’s Health

Updated Category News Views 99

A stubborn information gap is exactly where Tigerlily Foundation is planting its flag. The nonprofit’s new national HIV education and awareness campaign, THE POWER OF U, expands work that began in breast cancer advocacy into another area where women need clear facts, trusted voices, and room to speak without being shamed for needing answers. This is not a story that...

Continue Reading
ASA’s 2026 Grants Push Dermatology Into New Terrain

Updated Category News Views 104

Thirteen Small Bets With Serious Human Stakes Skin science rarely gets the splashy headlines, yet it touches a staggering number of people and carries some very stubborn unanswered questions. American Skin Association’s 2026 grant class puts 13 awards across skin cancer and dermatologic disease, with a noticeable willingness to follow newer clinical terrain rather than...

Continue Reading
Protein Now! Gains Clinician Attention, With Caveats

Updated Category News Views 91

A Small Bottle Has Drawn a Crowd Protein powder tubs have been cluttering kitchens for years; a 3.38-fluid-ounce shot is a cleaner answer to the same daily hassle. NutraBio Labs says more than 800 physicians, nurse practitioners, and physician associates had added PROTEIN NOW! to their individual FrontrowMD patient pages as of November 2026. That earned the product a...

Continue Reading
Fluence Investors Face a November 27 Litigation Clock

Updated Category News Views 14

Six calendar squares are all that separate eligible Fluence investors from the November 27, 2026 lead-plaintiff deadline. That is not much time to locate trade confirmations, calculate losses, and decide whether taking a larger role in a securities case makes sense. The lawsuit is not a verdict, and anybody pretending otherwise is selling smoke. But the underlying...

Continue Reading
Africa Tech Festival Puts Trust Ahead of AI Hype Cycle

Updated Category News Views 75

Fifteen thousand people can fill a convention centre, but they cannot magically deliver a package, fund a small business, or repair harm from a bad automated decision. That rather useful dose of reality ran through the final day of Africa Tech Festival 2026 in Cape Town. The 29th edition drew more than 15,000 delegates across three days, and the strongest message was not...

Continue Reading
Epiroc Takes Live Remote Drilling to CES 2027 Stage

Updated Category News Views 48

A drill rig chewing through Virginia rock from a Las Vegas convention booth is either a serious industrial-tech moment or an expensive magic trick. At CES 2027, Epiroc intends to make the distinction painfully clear. From January 6 through 9, the Stockholm-based mining-equipment company and Luck Stone will connect Booth 7031 in the LVCC West Hall to a working quarry in...

Continue Reading
Healthcare's Prevention Puzzle Needs Better Incentives

Updated Category News Views 113

When Savings Belong to the Next Plan A patient changing insurance plans can turn prevention into nobody’s asset. That is the uncomfortable little engine inside Russell Greenfield’s recent argument: an insurer may pay today for a program that helps prevent chronic illness, only to watch the eventual savings land with another plan after the member moves on. The person...

Continue Reading

Top 5 Most Recently Viewed Articles

ICG Enterprise Trust plc Announces Share Repurchase Details

Updated Category News Views 159

ICG Enterprise Trust plc Share Buyback Announcement ICG Enterprise Trust plc (the “Company”) The Company has announced a recent development regarding its share buyback initiative. On a significant date, it repurchased 15,000 of its own shares aimed to be held as treasury shares, with each share valued at an average price of 1450 pence. Details of the Transaction...

Continue Reading
Converge Technology Solutions Shares Third Quarter 2024 Insights

Updated Category News Views 217

Converge Technology Solutions Announces Preliminary Q3 Results Converge Technology Solutions Corp. (CTS) has released its preliminary unaudited financial results for the third quarter of 2024. The company is committed to delivering insightful updates to its stakeholders as part of its transparency approach. The company stated that all figures are presented in Canadian...

Continue Reading
Discovery Silver Corp. Unveils 2023 ESG Report

Updated Category News Views 104

Discovery Silver Corp. Releases 2023 ESG Report Key Highlights: Earned Quality Environmental Certification from the Mexican Government Recognized as a Socially Responsible Enterprise by the Mexican Center for Philanthropy Achieved Great Place to Work Certification Discovery Silver Corp. (TSX: DSV, OTCQX: DSVSF) is excited to announce the publication of its 2023...

Continue Reading
Final Call for Subscription in IDEX Biometrics Offering Today

Updated Category News Views 152

Important Subscription Period Details for IDEX Biometrics Today marks a significant turning point for IDEX Biometrics ASA as the subscription period for their subsequent offering of shares closes. The company previously announced that they aim to issue up to 600 million new shares at a remarkable subscription price of NOK 0.01 per share. This offering, essential for...

Continue Reading
Dundee Corporation Strengthens Position in Greenheart Gold Inc.

Updated Category News Views 33

Overview of Recent Acquisition Dundee Corporation (TSX: DC.A) has announced that its wholly-owned subsidiary, Dundee Resources Limited, recently acquired 2,000,000 common shares of Greenheart Gold Inc. (TSXV: GHRT) at a price of C$0.50 per share, totaling an investment of C$1,000,000. This acquisition is part of the Issuer's bought deal private placement and signifies...

Continue Reading